The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids
Open accessAbstract
Immunotherapy using chimeric antigen receptor (CAR)-engineered lymphocytes has shown impressive results in leukemia. However, for solid tumors such as colorectal cancer (CRC), new preclinical models are needed that allow to test CAR-mediated cytotoxicity in a tissue-like environment. Here, we developed a platform to study CAR cell cytotoxicity against 3-dimensional (3D) patient-derived colon organoids. Luciferase-based measurement served as a quantitative read-out for target cell viability. Additionally, we set up a confocal live imaging protocol to monitor effector cell recruitment and cytolytic activity at a single organoid level. As proof of principle, we demonstrated efficient targeting in diverse organoid models using CAR-engineered NK-92 cells directed toward a ubiquitous epithelial antigen (EPCAM). Tumor antigen-specific cytotoxicity was studied with CAR-NK-92 cells targeting organoids expressing EGFRvIII, a neoantigen found in several cancers. Finally, we tested a novel CAR strategy targeting FRIZZLED receptors that show increased expression in a subgroup of CRC tumors. Here, comparative killing assays with normal organoids failed to show tumor-specific activity. Taken together, we report a sensitive in vitro platform to evaluate CAR efficacy and tumor specificity in a personalized manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-tumor cells from adjacent normal tissue in biopsies or surgically resected samples can be used to develop control healthy organoids to confirm the tumor-specific efficacy of the tested drugs155.”
From Organoids (2022) · cites this paper as [155]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Sato, T., Stange, D. E., Ferrante, M., Vries, R. G. J., van Es, J. H., van den Brink, S., van Houdt, W. J., Pronk, A., van Gorp, J., Siersema, P. D., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.050 · Cited by 3,753
Organoid Models and Applications in Biomedical Research
Xinaris, C., Brizi, V., & Remuzzi, G. (2015) · The Nephron journals/Nephron journals · doi:10.1159/000433566 · Cited by 3,519
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · cited 1×
“…for other major cancer entities such as carcinomas of the breast, prostate, stomach, pancreas, and liver (Gao et al , 2014; Boj et al , 2015; Broutier et al , 2017; Sachs et al , 2018; Seidlitz et al , 2018), the co-culture work-flows established herein may provide a valuable tool for…”
Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135 · cited 2×
“As a demonstration of the great potential of organoid systems for the development of cancer immunotherapies, tumor-reactive T cells have recently been expanded from peripheral blood using co-cultures of matched CRC organoids (Dijkstra et al , 2018).”
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,033
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors
Koo, B.-K., Spit, M., Jordens, I., Low, T. Y., Stange, D. E., van de Wetering, M., van Es, J. H., Mohammed, S., Heck, A. J. R., Maurice, M. M., et al. (2012) · Nature · doi:10.1038/nature11308 · Cited by 980
ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner
Hao, H.-X., Xie, Y., Zhang, Y., Charlat, O., Oster, E., Avello, M., Lei, H., Mickanin, C., Liu, D., Ruffner, H., et al. (2012) · Nature · doi:10.1038/nature11019 · Cited by 962
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.11 · Cited by 911
Fujii, M., Shimokawa, M., Date, S., Takano, A., Matano, M., Nanki, K., Ohta, Y., Toshimitsu, K., Nakazato, Y., Kawasaki, K., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.04.003 · Cited by 852
Gong, J.-H., Maki, G., & Klingemann, H.-G. (1994) · PubMed · Cited by 727
Redundant sources of Wnt regulate intestinal stem cells and promote formation of Paneth cells
Farin, H. F., Van Es, J. H., & Clevers, H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.08.031 · Cited by 655
Self-citationGurney, A., Axelrod, F., Bond, C. J., Cain, J., Chartier, C., Donigan, L., Fischer, M., Chaudhari, A., Ji, M., Kapoun, A. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120068109 · Cited by 614 · cited 6×
“As an example, we generated and tested a novel CAR-based on a therapeutic antibody (OMP-18R5) that effectively blocks FZD receptors (Gurney et al , 2012).”
InfluentialEpithelial Cell Adhesion Molecule
Trzpis, M., McLaughlin, P. M. J., de Leij, L. M. F. H., & Harmsen, M. C. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070152 · Cited by 579
Visualization of a short-range Wnt gradient in the intestinal stem-cell niche
Farin, H. F., Jordens, I., Mosa, M. H., Basak, O., Korving, J., Tauriello, D. V. F., de Punder, K., Angers, S., Peters, P. J., Maurice, M. M., et al. (2016) · Nature · doi:10.1038/nature16937 · Cited by 525
Self-citationRNF43 is frequently mutated in colorectal and endometrial cancers
Giannakis, M., Hodis, E., Mu, X. J., Yamauchi, M., Rosenbluh, J., Cibulskis, K., Saksena, G., Lawrence, M. S., Qian, Z. R., Nishihara, R., et al. (2014) · Nature Genetics · doi:10.1038/ng.3127 · Cited by 490
Mlecnik, B., Bindea, G., Kirilovsky, A., Angell, H. K., Obenauf, A. C., Tosolini, M., Church, S., Maby, P., Vasaturo, A., Angelova, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6352 · Cited by 475
Noel, G., Baetz, N. W., Staab, J. F., Donowitz, M., Kovbasnjuk, O., Pasetti, M. F., & Zachos, N. C. (2017) · Scientific Reports · doi:10.1038/srep45270 · Cited by 420
Tang, X., Yang, L., Li, Z., Nalin, A. P., Dai, H., Xu, T., Yin, J., You, F., Zhu, M., Shen, W., et al. (2018) · Europe PMC (PubMed Central) · Cited by 406
The epidermal growth factor receptor variant III ( EGFR v III ): where wild things are altered
Gan, H. K., Cvrljevic, A. N., & Johns, T. G. (2013) · FEBS Journal · doi:10.1111/febs.12393 · Cited by 394
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P. S., Hattingen, E., Harter, P. N., Mittelbronn, M. G. A., Tonn, T., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 393
Self-citationSchwitalle, Y., Kloor, M., Eiermann, S., Linnebacher, M., Kienle, P., Knaebel, H. P., Tariverdian, M., Benner, A., & Doeberitz, M. V. K. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.015 · Cited by 386
Schönfeld, K., Sahm, C., Zhang, C., Naundorf, S., Brendel, C., Odendahl, M., Nowakowska, P., Bonig, H. B., Koehl, U., Kloeß, S., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.219 · Cited by 355
Self-citationEfficient Intracellular Delivery of Native Proteins
D’Astolfo, D. S., Pagliero, R. J., Pras, A., Karthaus, W. R., Clevers, H., Prasad, V., Lebbink, R. J., Rehmann, H., & Geijsen, N. (2015) · Cell · doi:10.1016/j.cell.2015.03.028 · Cited by 338
Human gastric cancer modelling using organoids
Seidlitz, T., Merker, S. R., Rothe, A., Zakrzewski, F., von Neubeck, C., Grützmann, K., Sommer, U. J., Schweitzer, C., Schölch, S., Uhlemann, H., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314549 · Cited by 333
NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Suck, G., Odendahl, M., Nowakowska, P., Seidl, C., Wels, W. S., Klingemann, H., & Tonn, T. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1761-x · Cited by 332
Self-citationControlled gene expression in primary Lgr5 organoid cultures
Koo, B.-K., Stange, D. E., Sato, T., Karthaus, W., Farin, H. F., Huch, M., van Es, J. H., & Clevers, H. (2012) · Nature Methods · doi:10.1038/nmeth.1802 · Cited by 320
Self-citationZhang, C., Oberoi, P., Oelsner, S., Waldmann, A., Lindner, A., Tonn, T., & Wels, W. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00533 · Cited by 318
Self-citationHalama, N., Braun, M., Kahlert, C., Spille, A., Breunig, C., Rahbari, N. N., Koch, M., Weitz, J., Kloor, M., Zoernig, I., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2173 · Cited by 300
Farin, H. F., Karthaus, W. R., Kujala, P., Rakhshandehroo, M., Schwank, G., Vries, R. G. J., Kalkhoven, E., Nieuwenhuis, E. E. S., & Clevers, H. C. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20130753 · Cited by 275
Self-citationSwitching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
Cartellieri, M., Feldmann, A., Koristka, S., Arndt, C., Loff, S., Ehninger, A., Bonin, M. V., Bejestani, E. P., Ehninger, G., & Bachmann, M. P. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.61 · Cited by 255
Halle, S., Keyser, K. A., Stahl, F. R., Busche, A., Marquardt, A., Zheng, X., Galla, M., Heissmeyer, V., Heller, K., Boelter, J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.010 · Cited by 231
Sahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 192
Self-citationGenßler, S., Burger, M. C., Zhang, C., Oelsner, S., Mildenberger, I. C., Wagner, M., Steinbach, J., & Wels, W. S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1119354 · Cited by 188
Self-citationNozaki, K., Mochizuki, W., Matsumoto, Y., Matsumoto, T., Fukuda, M., Mizutani, T., Watanabe, M., & Nakamura, T. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1170-8 · Cited by 188
Porcupine inhibitor suppresses paracrine Wnt-driven growth of Rnf43;Znrf3 -mutant neoplasia
Koo, B., van Es, J. H., van den Born, M., & Clevers, H. C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508113112 · Cited by 157
New flow cytometric assays for monitoring cell-mediated cytotoxicity
Zaritskaya, L., Shurin, M. R., Sayers, T. J., & Malyguine, A. M. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.49 · Cited by 156
Baetz, N. W., Noel, G., Staab, J. F., Donowitz, M., Kovbasnjuk, O. N., Pasetti, M. F., & Zachos, N. C. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)30545-0 · Cited by 126
Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb
Weigelin, B., Bolaños, E., Teijeira, Á., Martínez‐Forero, I., Labiano, S., Azpilikueta, A., Morales‐Kastresana, A., Quetglas, J. I., Wagena, E., Sánchez-Paulete, A. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1506357112 · Cited by 118
A Simple and Sensitive Method for Measuring Tumor-Specific T Cell Cytotoxicity
Fu, X., Tao, L., Rivera, A. M., Williamson, S. M., Song, X., Ahmed, N. M., & Zhang, X. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011867 · Cited by 82
A 3-D enteroid-based model to study T-cell and epithelial cell interaction
Rogoz, A., Reis, B. S., Karssemeijer, R. A., & Mucida, D. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.03.014 · Cited by 75
Inderberg, E. M., Wälchli, S., Myhre, M. R., Trachsel, S., Almåsbak, H., Kvalheim, G., & Gaudernack, G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1302631 · Cited by 67
Hills, D., Rowlinson‐Busza, G., & Gullick, W. J. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630414 · Cited by 64
Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice
Pennell, C. A., Barnum, J. L., McDonald-Hyman, C. S., Panoskaltsis‐Mortari, A., Riddle, M. J., Xiong, Z., Loschi, M. L., Thangavelu, G., Campbell, H. M., Storlie, M. D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.006 · Cited by 59
Chen, H. J., Sun, J. M., Huang, Z., Hou, H., Arcilla, M., Rakhilin, N., Joe, D. J., Choi, J., Gadamsetty, P., Milsom, J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3239 · Cited by 34
Unicar: A Novel Modular Retargeting Platform Technology for CAR T Cells
Cartellieri, M., Loff, S., Bonin, M. V., Bejestani, E. P., Ehninger, A., Feldmann, A., Koristka, S., Arndt, C., Ehninger, G., & Bachmann, M. P. (2015) · Blood · doi:10.1182/blood.v126.23.5549.5549 · Cited by 21
Flagged first, then by citations
Cited by
Sorted by citations
Human organoids: model systems for human biology and medicine
Kim, J., Koo, B.-K., & Knoblich, J. A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0259-3 · Cited by 2,187
Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,082
NK cell-based cancer immunotherapy: from basic biology to clinical development
Liu, S., Galat, V., Galat4, Y., Lee, Y. K. A., Wainwright, D., & Wu, J. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01014-w · Cited by 689
Organoid and Spheroid Tumor Models: Techniques and Applications
Gunti, S., Hoke, A. T. K., Vu, K., & London, N. R. (2021) · Cancers · doi:10.3390/cancers13040874 · Cited by 525
Next-generation cancer organoids
LeSavage, B. L., Suhar, R. A., Broguière, N., Lütolf, M. P., & Heilshorn, S. C. (2021) · Nature Materials · doi:10.1038/s41563-021-01057-5 · Cited by 479
Metadata
- Authors
- Schnalzger, T. E., de Groot, M. H., Zhang, C., Mosa, M. H., Michels, B. E., Röder, J., Darvishi, T., Wels, W. S., & Farin, H. F.
- Affiliations
- University of Konstanz (DE)
- German Cancer Research Center (DE)
- Goethe University Frankfurt (DE)
- Corresponding author
- Farin, Henner F
- ORCID
- Venue
- The EMBO Journal
- Published
- 2019-04-29
- Volume
- 38
- Issue
- 12
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC6576164
- OpenAlex
- W2942656692
- Cited by
- 354
- References
- 57
- Citations by year
- 2026: 45 · 2025: 60 · 2024: 62 · 2023: 63 · 2022: 47 · 2021: 41 · 2020: 29 · 2019: 7
- FWCI
- 12.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The EMBO Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Frankfurt Cancer Institute (III L 5 ‐ 519/03/03.001 ‐ (0015))
- German Cancer Consortium
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- chimeric antigen receptor, colorectal cancer, 3D organoids, EpCAM, EGFRvIII, Frizzled receptors, tumor antigen specificity, luciferase reporter
- MeSH terms
- Receptors, Chimeric Antigen, Cells, Cultured, Cytotoxicity, Immunologic, Humans, Models, Biological, Organoids, Receptors, Antigen, T-Cell, Colorectal Neoplasms, Genetic Therapy, Immunotherapy, Adoptive, Tissue Culture Techniques, Tissue Scaffolds, HEK293 Cells, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
